CA58183/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1993	5
1994	3
1995	3
1996	8
1997	11
1998	12
1999	10
2000	2
2001	6
2002	4
2003	4
2004	13
2005	16
2006	6
2007	5
2008	10
2009	9
2010	6
2011	9
2012	9
2013	6
2014	9
2015	5
2024	0

1

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. Jeselsohn R, et al. Nat Rev Clin Oncol. 2015 Oct;12(10):573-83. doi: 10.1038/nrclinonc.2015.117. Epub 2015 Jun 30. Nat Rev Clin Oncol. 2015. PMID: 26122181 Free PMC article. Review.

2

Life and death by p53.

Elledge RM, Lee WH. Elledge RM, et al. Bioessays. 1995 Nov;17(11):923-30. doi: 10.1002/bies.950171105. Bioessays. 1995. PMID: 8526886 Review.

3

Escorting Ras.

Zheng ZY, Xu L, Bar-Sagi D, Chang EC. Zheng ZY, et al. Small GTPases. 2012 Oct-Dec;3(4):236-9. doi: 10.4161/sgtp.20460. Epub 2012 Jun 27. Small GTPases. 2012. PMID: 22735486 Free PMC article.

4

Targeting HER2 for the treatment of breast cancer.

Rimawi MF, Schiff R, Osborne CK. Rimawi MF, et al. Annu Rev Med. 2015;66:111-28. doi: 10.1146/annurev-med-042513-015127. Annu Rev Med. 2015. PMID: 25587647 Review.

5

Estrogen receptor mutations in human disease.

Herynk MH, Fuqua SA. Herynk MH, et al. Endocr Rev. 2004 Dec;25(6):869-98. doi: 10.1210/er.2003-0010. Endocr Rev. 2004. PMID: 15583021 Review.

6

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.

Massarweh S, Schiff R. Massarweh S, et al. Clin Cancer Res. 2007 Apr 1;13(7):1950-4. doi: 10.1158/1078-0432.CCR-06-2540. Clin Cancer Res. 2007. PMID: 17404074 Review.

7

The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer.

Allred DC, Brown P, Medina D. Allred DC, et al. Breast Cancer Res. 2004;6(6):240-5. doi: 10.1186/bcr938. Epub 2004 Sep 22. Breast Cancer Res. 2004. PMID: 15535853 Free PMC article. Review.

8

Prognostic factors: rationale and methods of analysis and integration.

Clark GM, Hilsenbeck SG, Ravdin PM, De Laurentiis M, Osborne CK. Clark GM, et al. Breast Cancer Res Treat. 1994;32(1):105-12. doi: 10.1007/BF00666211. Breast Cancer Res Treat. 1994. PMID: 7819579 Review.

9

The promise of microarrays in the management and treatment of breast cancer.

Chang JC, Hilsenbeck SG, Fuqua SA. Chang JC, et al. Breast Cancer Res. 2005;7(3):100-4. doi: 10.1186/bcr1018. Epub 2005 Apr 1. Breast Cancer Res. 2005. PMID: 15987438 Free PMC article. Review.

10

Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.

Fu X, Osborne CK, Schiff R. Fu X, et al. Breast. 2013 Aug;22 Suppl 2(0 2):S12-8. doi: 10.1016/j.breast.2013.08.001. Epub 2013 Sep 5. Breast. 2013. PMID: 24011769 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Results by year